1 S. Sundar, L Furber, D Cameron, P Leonard, C Humber, A Thomas, WP Steward, KJ O’Byrne. Phase I/II Study of Docetaxel in combination with the P-Glycoprotein-170 inhibitor Valspodar in Solid tumours. Proc Am Soc Clin Oncol 2002; 21(2): 92b. 2182.
2 Sundar Santhanam,, M Decatris, F J Madden. Trends in survival of patients diagnosed with primary Testicular tumours in Leicestershire: a 15-year experience (1983 – 1997). British Journal of Cancer. 2002. Vol 86 (suppl 1): S57. P76.
3 Sundar Santhanam, S Bolton, S Vasanthan, G Thomas. Safe delivery of Radiotherapy to patients with Implanted Cardiac Pacemakers. British Journal of Cancer. 2002.Vol 86 (suppl 1): S65. P103.
4 M P Decatris, K Jeffries, Sundar Santhanam, A Thomas, S Khanna, S Vasanthan, A Benghiat, R P Symonds, K O’Byrne, W P Steward. A Prospective Audit of Peripherally Inserted Central venous Catheters (PICCs). British Journal of Cancer. 2002.Vol 86 (suppl 1): S69. P117.
5 S. Sundar, A. Basu, M. Liddicoat, S.Vasanthan. Assessment of local spread and nodal metastatic disease in Prostate cancer: Correlation between Partin Tables (a staging nomogram) and MR Imaging features. European Radiology. 2002. Vol 12(6):D6-D7.
6 Sundar Santhanam, F J Madden. Patterns of Radiotherapy usage in 328 consecutive primary Testicular tumour patients: a 15-year experience (1983 to 1997). Radiotherapy and Oncology. 2002. Vol 64 (suppl 1): S304. P1041.
7 S. Sundar, A Mitchell, M Decatris, M Kumar, A Osman, S Khanna, S Vasanthan, P Symonds, K O’Byrne. Phase II study of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in patients with Epithelial Ovarian Cancer relapsing within 2 years of platinum based therapy. Annals of Oncology.2002.Vol 13 (Suppl 5):112. 410P.
8 S Mon, C Murray, S Sundar, T McCulloch, SY Chan. Analysis of DNA ploidy in borderline ovarian tumours. Proc Am Soc Clin Oncol 2003. A1968
9 AJ.Colquhoun, Sundar Santhanam, PH.Rajjayabun, RP. Symonds, JK. Mellon. Can inhibition of epidermal growth factor receptor (EGFR) with gefitinib (ZD1839) improve the response to radiation therapy in bladder cancer? Proc Am Soc Clin Oncol 2003. A919
10 M Decatris, S. Sundar, K O’Byrne. Platinum-based chemotherapy in metastatic breast cancer (MBC): The Leicester (UK) experience. Annals of Oncology.2003; 14: (iii) 56.
11 A.Colquhoun, S.Sundar, P.Rajjayabun, L.Griffiths, P.Symonds, K.Mellon. Epidermal growth factor receptor (EGFR) status predicts outcome following external beam radiation therapy for muscle-invasive bladder cancer. EAU Annual Congress.Vienna, 2004.
12 S Sundar, M Sokal, K Lees, L Osborne, J Carmichael. Phase II trial of Gemcitabine Carboplatin Combination in advanced transitional cell cancer (TCC) of bladder and urinary tract. Annals of Oncology. 2004; 15 Suppl 3;iii.118. 441P
13 RP. Symonds, DM.Kumar, S.Sundar, K.Ibrahim, B Savelyich, E.Miller. Information needs of Asian and White English cancer patients and their families in Leicestershire: a cross-sectional survey. British Journal of Cancer.2003: 88 (Suppl 1): S24: 7.8
14 S. Sundar, D.Fyfe, A.Dhadda, S.Khan,A.Conn. Impact of Neutropenia on delivering planned Chemotherapy for Solid tumors. Ann Oncol 2005. Vol 16,Suppl 2: ii320. 185P
15 A Dhadda, D Lakshmanan, M Sokal, S Sundar . Age does not influence acute toxicity during radiotherapy dose escalation for prostate cancer. European Journal of Cancer Supplements. ECCO 13 Abstract Book. October 2005. Volume 3, Issue 2, Pages 3-542. Abstract no: 1.279..
16 S.Sundar, A Wade, D Lakshmanan, A Dhadda, M Sokal. Male Cancer Patients’ attitudes towards female physicians, female nurses and chaperones during Urological consultations. European Journal of Cancer Supplements. ECCO 13 Abstract Book. October 2005. Volume 3, Issue 2, Pages 3-542. Abstract no: 1.327
17 Helal AM, Sundar S, Przeslak AJ, Perkins AC. A comparison of 3D conformal radiotherapy and IMRT treatment plans in prostate cancer. European Journal of Cancer Supplements. ECCO 13 Abstract Book. October 2005. Volume 3, Issue 2, Pages 3-542. Abstract no: 849.
18 C Joynson, P Symonds, S Sundar. Anaemia in patients with transitional cell carcinoma (TCC) of the bladder treated with radiotherapy. Journal of Clinical Oncology. 2006. Volume 24 (18S). 642: A14569.
19 A Helal S Sundar et al. The effect of target volume / OAR geometry on the dose distribution within rectum and bladder for IMRT treatment of prostate cancer. NCRI 2006 Cancer Conference. Birmingham B54: P101
20 A Chaudhuri, S Sundar. et al. The utility of routine urine cultures and serum biochemistry in prostate cancer patients undergoing radical 3D-conformal external beam radiotherapy. NCRI 2006 Cancer Conference. Birmingham. B53: P100
21 C Joynson, P Symonds, S Sundar. Anaemia in patients with transitional cell carcinoma (TCC) of the bladder treated with radiotherapy. NCRI 2006 Cancer Conference. Birmingham. B150: P132
22 A. M. Helal, A. Przeslak, S. Sundar, A. Perkins. Patient geometry and applicability of class solution for optimised intensity modulated radiotherapy dose distributions for prostate cancer. ASCO 2007 Prostate Cancer Symposium. Abstract no: 372.
23 Song, X., Petrovic, S., Sundar, S. “A Case-Based Reasoning Approach to Dose Planning in Radiotherapy”, in D.Wilson, D.Khemani (Eds.) Workshop Proceedings, The Seventh International Conference on Case-Based Reasoning ICCBR’07, Belfast, Northern Ireland, August 13-16, 2007, pp. 348-357.
24 Petrovic,S., Leung,W., Song,X., and Sundar,S., “Algorithms for radiotherapy treatment booking”, in R.Qu (Ed) Proceedings of the 25th Workshop of the UK Planning and Scheduling Special Interest Group (PlanSIG’2006) , Nottingham, UK, 14-15th December 2006, pp. 105-112.
25 S. Sundar, R. Cox. Re-induction of sensitivity to diethylstilbestrol in docetaxel-treated androgen refractory prostate cancer. ASCO 2008 Prostate Cancer Symposium. Abstract No: 172
26 Mishra N, Petrovic S, Sundar S, A Knowledge-light Nonlinear Case-based Reasoning Approach to Radiotherapy Planning, Proceedings of the 21st International Conference on Tools with Artificial Intelligence, ICTAI 2009, November 2-5, 2009, Newark USA, 776-783.
27 N. Mishra, S. Petrovic and S. Sundar, A Novel Case Based Reasoning Approach to Radiotherapy Planning, in Proceedings of the 18th Triennial Conference of the International Federation of Operational Research Societies (IFORS’08), Sandton, South Africa, 13-18 July, 2008, pp. 66.
28 N. Mishra, S. Petrovic, S. Sundar. A non-linear case based reasoning approach to radiotherapy dose planning, in Proceedings of the 35th annual Operational Research Applied to Health Services (ORAHS) Leuven, Belgium, 12-17 July, 2009, pp. 24. .pdf
29 N. Mishra, S. Petrovic, S. Sundar, Self-adaptive case based reasoning for dose planning in radiotherapy, in book of the 36th annual Operational Research Applied to Health Services (ORAHS), 18-23 July, 2010, pp. 28-46. .pdf
30 N. Mishra, S. Petrovic, S. Sundar. A novel case based reasoning approach to radiotherapy planning, Expert Systems with Applications, accepted for publication .pdf Expert Systems with Applications: Volume 38 Issue 9, September, 2011.http://dl.acm.org/citation.cfm?id=1975071
31 Richard Cox, Santhanam Sundar. Diethylstilboestrol is active in docetaxel treated androgen independent prostate cancer. NCRI Conference Abstracts. 2008. C115
32 D. Peel, S. Sundar. Metronomic Cyclophosphamide and Dexamethasone is Active in Docetaxel, Castration Refractory, Prostate Cancer. Clinical Oncology. Volume 21, Issue 10, December 2009, Page 801.
33 O. Matzinger; F. Duclos; A. Van den Bergh; C. Carrie; P. Kitsios; S. Villa; P. Poortmans; S. Sundar; L. Collette; M. Bolla. Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 151. Abstract O-2001.
34 Abi Pascoe, S Sundar. Prostate Radiation for Castration Refractory Prostate cancer. The 8th BUG Annual Meeting. September 2011. York. Clinical Oncology. Volume 24, Issue 2, March 2012, Pages 156.
35 R.A. Cox, E. Ferguson, S. Sundar . Validation of a Rating Scale to Assess the Effects of Testosterone Deficiency in Prostate Cancer Patients Taking Androgen Deprivation Therapy as an Adjunct to Radical Radiotherapy. EMCC. September 2011 European Journal of Cancer Vol. 47 Supplement 1, Page S497
36 A. Cox, N. Mishra, I. Sayers, S. Petrovic, S. Sundar. A Decision Aid for Radiotherapy Dose Selection in Prostate Cancer Based on Non-linear Case Based Reasoning . Clinical Oncology, Volume 23, Issue 3, April 2011, Pages S19-S20
37 P. Hoskin, S. Sundar, K. Reczko, S. Forsyth, N. Mithal, B. Sizer, L. Toy, M. Stratford, M. Jitlal et al. A Multicentre Randomised Trial of Ibandronate Compared to Single Dose Radiotherapy for Localised Metastatic Bone Pain in Prostate Cancer (RIB). EMCC. September 2011 European Journal of Cancer Vol. 47 Supplement 2, Page 6
38 Amit Bahl, Susan Masson, Zafar Malik, Alison J Birtle, Santhanam Sundar, Robert J Jones, Nicholas David James, Malcolm David Mason, Satish Kumar, David Bottomley, Anna Lydon, Simon Chowdhury, James Wylie, Johann Sebastian De Bono. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). 2012 Genitourinary Cancers Symposium . Abstract No: 44. J Clin Oncol 30, 2012 (suppl 5; abstr 44).
39 Bahl, A.K., Masson, S., Malik, Z., Birtle, A., Sundar, S., Jones, R., James, N., Mason, M., Kumar, S., Bottomley, D., Lydon, A., Chowdhury, S., Wylie, J., De Bono, J.. Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Interim Safety and Quality of Life (QOL) Data From the UK Early Access Programme. 27th Annual EAU Congress in Paris on 24-28 February 2012. Abstract no 129
40 G.A. Walker, C.J. Perry, S.Sundar. Radical prostate radiotherapy to M0 patients with a presenting PSA of more than 100. (ESTRO 31. Barcelona) Radiotherapy and Oncology 2012. Vol. 103: Supplement 1, Page S431(pdf).
41 C.J. Perry, G.A. Walker, S. Sundar . Does rectal diameter affect acute toxicity of radical radiotherapy for prostate cancer? (ESTRO 31. Barcelona) Radiotherapy and Oncology 2012: Vol. 103: Supplement 1, Page S430 (pdf).
42 Bahl A, Masson S, Malik Z, Birtle A, Santhanam Sundar, Jones R, James N, Mason M, Bottomley D, Lydon A, Chowdhury S, Wylie J, De Bono J; Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279). Abstract Number: 91. J ClinOncol 31, 2013 (suppl 6; abstr 91).
43 G. Walker, M. Panades†, T. Sreenivasan†, S. Sundar. Radical Radiotherapy is Effective in Patients with Ultra-high Presenting PSA Clinical Oncology. Clinical Oncology. Volume 25, Issue 4, April 2013, Pages e73.http://dx.doi.org/10.1016/j.clon.2012.12.023.
44 Silverman R, Smith L, Sundar S. ‘Is it my last christmas dinner?’ survival of cancer patients having palliative chemotherapy during christmas period.BMJ Support Palliat Care. 2014 Mar;4Suppl 1:A56. doi: 10.1136/bmjspcare-2014-000654.159. (pdf)
45 Abigail Pascoe; Santhanam Sundar, Langmack Keith; Jamie Mills. Prostate cancer radiotherapy: Absolute dose volume parameters are consistently and significantly associated with acute rectal toxicity. UKRO 2013; Abstract Book Page 9. Poster no: P010.
46 M. Bolla, P. Maingon, A.C.M. Van den Bergh, C. Carrie, S. Villa, P.Kitsios, P. Poortmans, S. Sundar, E.M. Van der Steen-Banasik, L.Collette. 3D-CRT/IMRT with/without short term androgen deprivation inlocalised T1b-cT2aN0M0 prostate cancer EORTC 22991. ESTRO 33. April 04-08, 2014 • Vienna, Austria. Radiotherapy and Oncology. Volume 111, Supplement 1, April 2014. Page 217 abstract: OC-0522.
47 M. Bolla, P. Maingon, F. van den Bergh, C. Carrie, S. Villa, P. Kitsios, Ph. Poortmans, S. Sundar, EM Vandersteen-Banasik and L. Collette.3D-CRT/IMRT with/without short term androgen deprivation in localized T1b-cT2aN0M0 prostatic carcinoma (EORTC 22991). ESTRO 2014.
48 R. Ferraldeschi, S. Slovin, S. Hussain, F. Saad, J. Garcia, F.F. Kabbinavar, N. Uppa, N.J.Vogelzang, B.J. Poiesz, E. Gelmann, J. Picus, D. Mahadevan, S. Sundar, A. Nikapota, S.Pacey, A. Og50anesian, L. Manlapaz-Espiritu, Y. Hao, H. Keer, J. de Bono. A phase 1/2 study of at13387, a heat shock protein 90 (hsp90) inhibitor in combination with abiraterone acetate (aa) and prednisone (p) in Patients (pts) with castration-resistant prostate cancer (mcrpc) no longer responding to AA. ESMO 2014. Abstract: 776P; Annals of Oncology, Volume 25, Supplement 4, 2014
49 K. Johnson, C. Perry, R. Silverman, S. Sundar. Rectal distension on prostate radiotherapy planning CT scan is not a negative prognostic factor in the modern era of image guided radiotherapy. EMUC 2014. European Urology Supplements 11/2014;P013. DOI: 10.1016/S1569-9056(14)61238-0.
50 M. Bolla, P. Maingon, A. Van Den Bergh, C. Carrie, S. Villa, P. Kitsios, P. Poortmans, S. Sundar, E. Van Der Steen-Banasik, L. Collette. Results of EORTC 22991: 3D-CRT/IMRT with or without 6-month androgen deprivation therapy in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991). EMUC 2014. European Urology Supplements. 11/2014; DOI: 10.1016/S1569-9056(14)61223-9.
51 Powles T, Wheater M ,Geldart T, Boleti E, Din O, Stockdale A, Sundar S, Robinson A, Ahmed I, Sarker S, Hussian S , Ralph C. A randomised phase II study of AZ2014 vs. everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC). ASCO GU Feb 2015. Abstract Number: 409. J ClinOncol 33, 2015 (suppl 7; abstr 409)
52 Christy Ralph, Thomas Powles, Matthew Wheater, Omar Din,Thomas Geldart, Ekaterini Boleti, Andrew Stockdale, Santhanam Sundar, Angus Robinson, Akhila Wimalasingham, Imtiaz Ahmed, Wendy Burke, Shah-Jalal Sarker, Syed Hussain. B62: A randomised phase II study of AZD2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC). NCRI Cancer Conference abstracts. Liverpool. Nov 2015.
53 Bolla M., Maingon P., Van Den Bergh A.C.M., Carrie C., Villa S., Kitsios P., Poortmans P., Sundar S., Van Der Steen-Banasik,E.M., Armstrong J., Bosset J-F., Herrera F., Pieters B., Coens C., Collette L.Effect of 6 months of androgen deprivation therapy on progression-free survival and quality of life in localized T1bcT2aN0M0 prostate cancer.EAU 2015 annual meeting. European Urology Supplements 04/2015; 14(2):e1021-e1021a. DOI:10.1016/S1569-9056(15)61009-0.
54 Sarah Thomason. S Sundar, H. Buchanan.A mixed-methods evaluation of anxiety in prostate cancer patients: neo-adjuvant hormones and radical radiotherapy. MASCC/ISOO Annual Meeting on Supportive Care in Cancer, Copenhagen, Denmark, 25-27 June, 2015.Support Care Cancer (2015) 23 (Suppl 1):S1–S388 ( DOI 10.1007/s00520-015-2712-y ) S254 18-47-P
55 S. Sundar, J. Do, M. O’Cathail. Public educational campaign needed to clear misconception about cardiopulmonary resuscitation in terminally ill cancer patients. MASCC/ISOO Annual Meeting on Supportive Care in Cancer, Copenhagen, Denmark, 25-27 June, 2015. Support Care Cancer (2015) 23 (Suppl 1):S1–S388 ( DOI 10.1007/s00520-015-2712-y ) S239 18-07-P
56 A. Pascoe, G. Walker, S. Sundar. Effect of Age on Rectal toxicity following radical Radiotherapy to Prostate cancer. European Society for Radiotherapy and Oncology (ESTRO) meeting. 3rd ESTRO Forum 24-28 April 2015 • Barcelona, Spain. radiotherapy and Oncology. Volume 115 Supplement 1 (2015) S690 EP-1277 2015 .
57 Thomason S, Sundar S, Buchanan H. A Mixed-Methods Evaluation of Anxiety in Prostate Cancer Patients: Neo-adjuvant Hormones and Radical Radiotherapy. Psycho-Oncology 24 (Supp. 1): 1–15 (2015). (DOI: 10.1002/pon.3824) Page 7. http://onlinelibrary.wiley.com/doi/10.1002/pon.3824/pdf
58 M. O’Cathail, T. Aghadiuno, G. Walker, F. Burge, S. Sundar. Neutrophil-Lymphocyte Ratio (NLR) is a prognostic factor for survival but not a predictive factor for Abiraterone treatment response in Docetaxel naive and Docetaxel treated mCRPC patients. 7th European Multidisciplinary Meeting on Urological Cancers in Barcelona on 12-15 November 2015. EMUC poster presentations. European Urology supplements 14 (2015) 149–221. page 188. P089
59 Thomas Powles, Robert Anthony Huddart, Tony Elliott, Robert Jones, Syed A. Hussain, Simon J. Crabb, Charlotte Ackerman, Satinder Jagdev, John D. Chester, Serena Hilman, Mark Beresford, A. Graham Macdonald, Santhanam Sundar, John A. Frew, Andrew Stockdale, Shah-Jalal Sarker, Daniel Berney, Simon Chowdhury. . A Phase II/III Double Blind Randomised Trial Comparing Maintenance Lapatinib Versus Placebo After First Line Chemotherapy In HER1/2 Positive Metastatic Bladder Cancer Patients. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number: 4505. J ClinOncol 33, 2015 (suppl; abstr 4505)
60 Michel Bolla, Alphonsus C.M. Van Den Bergh, Christian Carrie, Salvador Villà, PetrosKitsios, Philip M. Poortmans, Santhanam Sundar, Elzbieta M. van der Steen-Banasik, John Armstrong, Jean-Francois Bosset, Fernanda Herrera, Bradley Pieters, Annerie Slot, Amit Bahl, Laurence Collette, Philippe Maingon. EORTC trial 22991: Results of a phase III study. comparing 6 months of androgen suppression and irradiation versusirradiation alone for localized T1b-cT2aN0M0 prostate cancer. ASCO 2016 Genitourinary Cancers Symposium (January 7-9, 2016). Abstract Number: 22. J Clin Oncol 34, 2016 (suppl 2S; abstr 22)
61 Santhanam Sundar, Theresa Teoh Chiu Hoong, Anmar Alharganee A confirmatory survey regarding public misconception about cardiopulmonary resuscitation (CPR) in advanced cancer patients. 2016 ASCO Annual Meeting Abstracts. J ClinOncol 34, 2016 (suppl; abstr e21507).
62 Santhanam Sundar, Ananth Sivanandan, Georgina Walker. Concurrent boost technique in prostate IMRT and accuracy of planning target volume (PTV) at the periphery. 2016 ASCO Annual Meeting Abstracts. J ClinOncol 34, 2016 (suppl; abstr e16615).
63 Sarah Taylor, Santhanam Sundar; Tolerability and efficacy of lower dose of cabazitaxel (≤ 20mg/m2) in castration-refractory prostate cancer (CRPC). | 2016 ASCO Annual Meeting Abstracts. J ClinOncol 34, 2016 (suppl; abstr e16545).
64 Sivanandan M.A., Walker G. A. & Sundar S. Concurrent boost technique in prostate IMRT under-treats significant proportion of planning target volume (PTV) at periphery. UK Radiation Oncology Conference UKRO 2016. Liverpool 6-8 June 2016. O-046 page 30 https://profileproductions.eventtrac.co.uk/system/attachments/1650/original/UKRO_UKRC_POSTER_BOOK_2016.pdf
65 S. Sundar, H.D. Johnson, S. Taylor, S. Thomason; Are the newer chemotherapy drugs worth their high cost? – A survey of UK Public’s perception of reasonable price for chemotherapy drugs according to their health benefit. ESMO Annual Congress Copenhagen – Denmark, 7-11 October 2016 .Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377
66 S. Iqbal, W. Badreldin, S. Sundar, N. Thompson, J. Tanguay. Comparison of Axitinib and Everolimus in the Second Line Treatment of Metastatic Renal Cell Carcinoma Following Previous Treatment with a Tyrosine Kinase Inhibitor: a Multicentre Retrospective Analysis. BUG Meeting 2015. Clnical Oncology. May 2016. Volume 28, Issue 5, Pages e15–e16. DOI: http://dx.doi.org/10.1016/j.clon.2015.12.022
67 Thomas Powles, Syed A. Hussain, Andrew Protheroe, Alison Birtle, Prabir R Chakraborti, Robert Huddart, Satinder Jagdev, Amit Bahl, Andrew Stockdale, Santhanam Sundar, Simon J. Crabb, Judith Dixon-Hughes, Laura Alexander, Caroline A Bray, Jamie Stobo, Akhila Ganeshi Wimalasingham, Charlotte Ackerman, James Paul, Rob Jones. PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.ASCO GU 2016 meeting. J Clin Oncol 34, 2016 (suppl 2S; abstr 430)
68 Masters B., Mandeir J., O’Shaughnessy J., Sundar S. Perceptions of Success Rates of Cardiopulmonary Resuscitation: The Next Generation. Masters B. 15th World Congress of the European Association for Palliative Care, 18 – 20 May 2017,Madrid, Spain. European Journal of Palliative Care. Abstract book.2017. Abstract no: P01-173. Page 418.
69 J Price, S Sundar. Benchmarking 90-day mortality and 1 year survival for complex multi-fraction palliative radiotherapy. British Institute of Radiology.Palliative Radiotherapy. London 24 March 2017.
70 Santhanam Sundar, James Price, Kirsty Clarke, Thomas Wolfe, D Thurairasa, Ewan Shawcroft; Biomarker to cost-effectively harness the technical prowess of palliative radiation: Neutrophil lymphocyte ratio (NLR) and overallsurvival following palliative radiotherapy in an unselected real-worldpopulation of all tumor sites. ASCO Annual meeting 2017 Chicago. J ClinOncol 35, 2017 (suppl; abstr 10111).
71 Price, James; Clarke, Kirsty; Wolfe, Thomas; Shawcroft, Ewan; Sundar, Santhanam. Mortality and survival differences between patients undergoing single and multi-fraction palliative radiotherapy – is there scope for optimisation of resource utilisation? UKRO Congress 2017 . Manchester June 2017. Abstract no: 3674289.
72 Masters, Ben; Pascoe, Abi; Shawcroft, Ewan; Walker, Georgina; Sundar, Santhanam. Is rectum radiobiologically made up “serial or parallel” functional sub-units (FSU) – an exploratory study of rectal dose-volume and toxicity parameters. UKRO Congress 2017 . Manchester June 2017. Abstract no:3674151
73 Luren C. Harshman, John Logue, Cora Sternberg, Santhanam Sundar, Dirk Schrijvers, ClaesGinman, Martin Schostak, John Sylvester, Saby George, Marcello Tucci, Constantine Mantz, Pablo Borrega, Patrick Ziem, Raoul Concepcion, Kurt Miller, Oliver Sartor, JánKalinovský, Yoriko De Sanctis, Bertrand Tombal. “First Interim Results of the Radium-223 (Ra-223) REASSURE Observational Study: Analysis of Patient (Pt) Characteristics and Safety by Use of Abiraterone and/or Enzalutamide (Abi/Enza)” .ESMO Congress 2017, 8-12 September 2017, Madrid, Spain. ESMO 2017 Congress Abstract Book. Annals of Oncology 2017 Supplement 5 Volume 28 Page 279.Abstract no 807P.
74 S Sundar, J Price, T Wolfe, E Shawcroft, D Thurairasa. Prognostic Nutritional Index (PNI) for cost effective utilisation of newer, expensive radiation technology for palliative treatment of all cancer patients with limited life expectancy. ESMO 2017 Congress Abstract Book. Annals of Oncology 2017 Supplement 5 Volume 28 Page 499. Abstract number: 1391P
75 Micheal O’Cathail, Jessica Little, Shaymaa Hosni, Santhanam Sundar. Validation of a testosterone-deficiency symptoms rating-scale in prostate cancer patients treated with androgen deprivation therapy and radiotherapy.ASCO GU 2018 Genitourinary Cancers Symposium San Francisco.(February 8-10, 2018). J Clin Oncol 36, 2018 (suppl 6S; abstr 63).
76 M. O’Cathail, S. Sundar et al. Validating the use of the Aging Men’s Symptoms score as screening tool for anxiety and depression in non-metastatic prostate cancer patients receiving androgen deprivation therapy. EAU 2018 Meeting .(accepted)